Endobronchial treatment of benign endobronchial neoplasms: Our 10 years of experience

• Published in: Türk göğüs kalp damar cerrahisi dergisi 2021-01, Vol.29 (1), p.61-69
• Main Authors: Turan, Demet, Akif Özgül, Mehmet, Cengiz Seyhan, Ekrem, Uğur Chousein, Efsun, Özgül, Güler, Çetinkaya, Erdoğan
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 1301-5680; 2149-8156
• DOI: 10.5606/tgkdc.dergisi.2021.19488

The aim of the study was to assess the safety, efficacy, complications, and long-term outcomes of endobronchial treatment for benign endobronchial tumors. A total of 53 patients (39 males, 14 females; mean age: 53.7 years; range, 12 to 83 years) with the diagnosis of benign endobronchial neoplasms in our center between November 2010 and September 2019 were retrospectively analyzed. Data including demographic and clinical characteristics of the patients and treatment outcomes were examined. Tumors regressed in all patients with argon plasma coagulation, diode laser and electrocautery, which was combined with cryotherapy in some cases. Complications were observed in five (9%) patients. Major complications were atrial fibrillation in two patients and respiratory failure requiring mechanical ventilation in one patient. Minor complications were minimal bleeding in two patients. The response was very good in 39 (74%) patients and good in 12 (23%) patients. There was no significant difference in the residual tissue formation requiring cryotherapy among the endobronchial treatment modalities (p>0.05). The five-year survival rate was 94%. No endobronchial treatment-related mortality was observed in any of the patients. Endobronchial treatment modalities including diode laser, electrocautery, and argon plasma coagulation combined with or without cryotherapy are effective and safe in the treatment of benign endobronchial tumors.